JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ
Quotient CEO Franz Walt was interviewed on 05 May 2020 by Mike Graham on talkRADIO. They discussed the recently CE marked MosaiQ COVID-19 Antibody microarray, antibody testing, and the global COVID-19 pandemic.
JERSEY, Channel Islands, 1 May, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In V
JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test.
JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test.
Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies.
Quotient warns global shortages of critical components could hamper efforts
To read the full article, visit: Financial Times
JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1
